No Data
Be Wary Of Dian Diagnostics GroupLtd (SZSE:300244) And Its Returns On Capital
China Galaxy Securities: Deepseek is sparking a trend in AI Medical, which is expected to continuously enhance the valuation of the Medical Sector.
Medical is one of the most important and promising scenarios for AI applications, primarily centered on the resonance between AI large model inference capabilities and Medical Big Data. Industry pharmaceutical companies are rapidly deploying localized applications of deepseek, significantly enhancing the performance of specialized large models.
Huawei will release AI pathology models, and the Medical Industry is迎来 an important opportunity for intelligent upgrades.
① Huawei's data storage public account released information stating that it will launch the Ruijin pathological model based on the Huawei DCS AI solution. ② Jianghai Securities pointed out that under the guidance of the Health China 2030 Global Strategy, the Medical Industry is ushering in an important opportunity for intelligent upgrades.
Dragon Tiger List | Dian Diagnostics Group hits the 20 cm daily limit, HK->SZ net Sell of 0.1 billion yuan.
Dian Diagnostics Group (300244.SZ) hit the 20cm limit up at the close today, with a transaction amount of 1.45 billion yuan and a Turnover Ratio of 21.23%. According to the Dragon and Tiger List data, HK->SZ bought 59.227 million yuan while selling 0.16 billion yuan, resulting in a net sell of 0.1 billion yuan; four Institutions bought 42.1556 million yuan while selling 74.69 million yuan, resulting in a net sell of 32.5344 million yuan. (Ge Long Hui)
Is Dian Diagnostics GroupLtd (SZSE:300244) Using Too Much Debt?
Dean Diagnosis: 2024 Annual Results Forecast
Dian Diagnostics GroupLtd (SZSE:300244) Adds CN¥362m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 41%
